Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)
Brief Summary: This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are refractory to, a single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) and are ineligible for hematopoietic stem cell transplant (based on age, performance status, and/or comorbidities). Subjects will receive treatment with lisocabtagene maraleucel and will be followed for 2 years for safety, pharmacokinetics and biomarkers, disease status, quality of life, and survival.


Options:
A: Arm Label: Nivolumab monotherapy (Dose Escalation); Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Nivolumab + Lirilumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Lirilumab | Arm Label: Nivo + Dara + Pom + Dexa vs. Nivo + Dara; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Daratumumab, Drug: Pomalidomide, Drug: Dexamethasone | Arm Label: Daratumumab vs. Nivolumab + Daratumumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Daratumumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Daratumumab vs. Nivolumab + Daratumumab, Nivo + Dara + Pom + Dexa vs. Nivo + Dara, Nivolumab + Ipilimumab, Nivolumab + Lirilumab, Nivolumab monotherapy (Dose Escalation) | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Nivolumab + Ipilimumab | Intervention Type: BIOLOGICAL; Name: Lirilumab; Assigned to Arm(s): Nivolumab + Lirilumab | Intervention Type: BIOLOGICAL; Name: Daratumumab; Assigned to Arm(s): Daratumumab vs. Nivolumab + Daratumumab, Nivo + Dara + Pom + Dexa vs. Nivo + Dara | Intervention Type: DRUG; Name: Pomalidomide; Assigned to Arm(s): Nivo + Dara + Pom + Dexa vs. Nivo + Dara | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Nivo + Dara + Pom + Dexa vs. Nivo + Dara
B: Arm Label: 1A/T cell Arm (closed); Type: EXPERIMENTAL; Interventions: Procedure: Allogeneic stem cell transplant, Biological: Anti-CD19-chimeric-antigen-receptor-transduced T cells | Arm Label: 1B/T memory stem cell arm; Type: EXPERIMENTAL; Interventions: Procedure: Allogeneic stem cell transplant, Biological: Anti-CD19-chimeric-antigen-receptor-transduced T cells | Arm Label: 2/Donor arm; Type: OTHER; Interventions: Procedure: Leukapheresis | Intervention Type: PROCEDURE; Name: Allogeneic stem cell transplant; Assigned to Arm(s): 1A/T cell Arm (closed), 1B/T memory stem cell arm | Intervention Type: BIOLOGICAL; Name: Anti-CD19-chimeric-antigen-receptor-transduced T cells; Assigned to Arm(s): 1A/T cell Arm (closed), 1B/T memory stem cell arm | Intervention Type: PROCEDURE; Name: Leukapheresis; Assigned to Arm(s): 2/Donor arm
C: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Biological: lisocabtagene maraleucel | Intervention Type: BIOLOGICAL; Name: lisocabtagene maraleucel; Assigned to Arm(s): Treatment
D: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Biological: CD19 CAR T cells | Intervention Type: BIOLOGICAL; Name: CD19 CAR T cells; Assigned to Arm(s): Single Arm

Answer: C